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Mesenchymal stem cells (MSCs) are gaining relevance for treating equine joint injuries because of their ability to limit inflammation and 
stimulate regeneration. Because inflammation activates MSC immunoregulatory function, proinflammatory priming could improve MSC 
efficacy. However, inflammatory molecules present in synovial fluid or added to the culture medium might have deleterious effects on MSCs. 
Therefore, this study was conducted to investigate the effects of inflammatory synovial fluid and proinflammatory cytokines priming on 
viability and plasticity of equine MSCs. Equine bone marrow derived MSCs (eBM-MSCs) from three animals were cultured for 72 h in media 
supplemented with: 20% inflammatory synovial fluid (SF); 50 ng/mL IFN- and TNF- (CK50); and 20 ng/mL IFN- and TNF- (CK20). 
Proliferation assay and expression of proliferation and apoptosis-related genes showed that SF exposed-eBM-MSCs maintained their viability, 
whereas the viability of CK primed-eBM-MSCs was significantly impaired. Tri-lineage differentiation assay revealed that exposure to 
inflammatory synovial fluid did not alter eBM-MSCs differentiation potential; however, eBM-MSCs primed with cytokines did not display 
osteogenic, adipogenic or chondrogenic phenotype. The inflammatory synovial environment is well tolerated by eBM-MSCs, whereas 
cytokine priming negatively affects the viability and differentiation abilities of eBM-MSCs, which might limit their in vivo efficacy.
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Introduction
Articular pathologies such osteoarthritis (OA) are common 
diseases in both equines and humans, greatly impacting the 
daily lives of afflicted individuals and acting as a major cause of 
wastage in the equine industry. Horses have a double role in 
joint pathologies because they commonly suffer from these 
diseases [32], and they are considered the most suitable animal 
model for testing cell based therapies for human joint injuries 
[3]. Osteoarthritis is a complex condition characterized by damage 
to the articular cartilage. Inflammation plays an important role 
in progression of the disease as the secretion of proinflammatory 
mediators accelerates cartilage degradation. Conventional 
treatments primarily focus on relieving this inflammation and 
controlling pain [11]. An ideal therapeutic approach should stop 
progressive loss of cartilage and stimulate the regeneration of 
damaged structures. Treatments for equine joint diseases based 
on the intra-articular (IA) administration of mesenchymal stem 
cells (MSCs) are gaining importance because of their regenerative 
role [8]. MSCs show significant potential for cartilage repair, 
which is attributed to their trophic and differentiation properties, 
as well as their immunoregulatory ability [21]. The expression 
of immunoregulatory molecules by MSCs is regulated by 
proinflammatory cytokines such interferon- (IFN-), particularly 
in combination with tumor necrosis factor- (TNF-) [29], 
which suggests that MSC full immunoregulatory function 
depends on their activation after inflammatory exposure. 
Therefore, MSC priming with proinflammatory cytokines prior 
to their use in vivo might enhance their therapeutic efficacy [5].
Joint injuries result in a variable release of different 
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inflammatory molecules into the synovial fluid. Inflammatory 
synovial fluid may affect the function and characteristics of IA 
administered MSCs, such as migratory function or 
differentiation potential [16], or act as inductors of 
MSC-immune regulation in equine and human species [18,37]. 
However, the stimulus exerted by synovial fluid could be 
heterogeneous because variation exists between patients, even 
within one disease group [18]. Therefore, the combination of 
definite doses of INF with TNF- leads to a more homogenous 
stimulus for inducing MSC immunomodulation, which could 
improve their therapeutic potential. However, the regenerative 
potential of MSCs through differentiation could be decreased 
by inflammatory exposure [7,17,20]. In addition, IFN- and 
TNF- synergistically impair MSC self-renewal, decreasing 
their effectiveness [38]. To the best of our knowledge, the effects 
of these cytokines on these properties in equine MSCs have not 
yet been elucidated.
Because pre-existing joint inflammation may alter the 
therapeutic efficacy of MSCs when they are IA administered 
[31], further knowledge of the changes induced in equine MSCs 
by an inflammatory environment is necessary. Conversely, the 
use of IFN- and TNF- priming without detriment of viability 
and plasticity is of major interest to improve cellular therapies. 
Thus, this study was conducted to assess the possible effects of 
different inflammatory stimuli on viability and differentiation 
potential of equine bone marrow derived MSCs (eBM-MSCs) 
as a step prior for their clinical use in joint injured patients. 
Materials and Methods
Experimental design 
Equine BM-MSCs (n = 3) were exposed to three different 
inflammatory conditions and their responses were analyzed: 
Experiment 1 (SF), 20% allogeneic inflammatory synovial 
fluid was added to the culture medium to mimic the joint 
inflammatory environment; Experiment 2 (CK50), IFN- (50 
ng/mL) and TNF- (50 ng/mL) were added to the culture 
medium; and Experiment 3 (CK20), IFN- (20 ng/mL) and 
TNF- (20 ng/mL) were added to the culture medium. All 
inflammatory conditions were maintained for 72 h. Subsequently, 
a proliferation assay was conducted for 7 days. Expression of 
proliferation and apoptosis related genes was analyzed by real 
time quantitative polymerase chain reaction (RT-qPCR). 
Tri-lineage differentiation potential was examined through 
specific staining and gene expression by RT-qPCR. Triplicate 
controls were run in each experiment using the same 
eBM-MSCs (n = 3) cultured with control media.
Animals
Four geldings, named as EQ01, EQ02, EQ03 and EQ04 (weight, 
450–500 kg; age, 6–12 years), were used in this study. The 
horses were patients from the Veterinary Hospital of the 
University of Zaragoza suffering from varying types of 
locomotor system injuries, but determined to be in systemic 
good health based on clinical and hematologic examination. 
Biological samples (bone marrow [BM] and synovial fluid) 
were obtained with owner consent and according to local 
animal welfare regulations.
All procedures were carried out within the Project License 
31/11 approved by the in-house Ethic Committee for Animal 
Experiments of the University of Zaragoza. The care and use of 
animals were in accordance with the Spanish Policy for Animal 
Protection RD53/2013, which meets the European Union 
Directive 2010/63 on the protection of animals used for 
experimental and other scientific purposes.
Harvesting and characterization of eBM-MSCS 
A total of 40 mL of BM from the sternum were collected in 
heparinized syringes using a 11 g × 101 mm Jamshidi needle 
(CareFusion, USA) from three donors (EQ01, EQ02 and 
EQ03). Equine BM-MSCs were isolated using a gradient 
density separation technique as previously described by our 
group [27]. The cells were plated and cultured in basal culture 
medium consisting of low glucose Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 1% glutamine, 1% 
streptomycin/penicillin and 10% fetal bovine serum (FBS) 
(all from Sigma-Aldrich, USA) [27]. Cells were expanded until 
the third passage, then characterized by phenotype determination 
(flow cytometry and gene expression) and tri-lineage differentiation 
as previously described [27]. Cells were subsequently frozen in 
10% DMSO-90% FBS (Sigma-Aldrich) frozen medium and 
cryopreserved until experiments started. 
Inflammatory synovial fluid collection
Synovial fluid was harvested from EQ04, which presented 
aseptic synovitis in one tarso-crural joint. Arthrocentesis was 
performed to reduce the joint effusion and aspirated synovial 
fluid was collected in heparin-treated tubes (Becton, Dickinson 
and Company, USA) and used for Experiment 1. Synovial fluid 
inflammatory status was verified by measuring total protein 
(g/dL) with a portable optical refractometer (RHB-32 Hand-held 
Brix Refractometer; Spectrum Technologies, USA), by 
conducting a cytological examination and determine the 
concentration of the acute phase proteins (APPs) serum amyloid 
A (SAA) and haptoglobin (Hp) [2]. Subsequently, synovial fluid 
was centrifuged at 3,000 × g for 15 min, after which the 
supernatant was stored at −80oC. All processes were performed 
under aseptic conditions to prevent culture contamination.
Equine BM-MSCs culture under inflammatory conditions
The cytokines used for CK priming were selected based on 
their described synergy [30]. Synovial fluid and CK inflammatory 
conditions were determined according to previous reports 
[29,35,37,39]. The time of exposure was determined to be 72 h 
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[26] for the three conditions. For Experiment 1, inflammatory 
synovial fluid was added to the basal culture medium at 20% 
(SF medium). For Experiments 2 and 3, basal media were 
supplemented with recombinant equine TNF- and IFN- 
(R&D Systems, USA) by adding 50 ng/mL of each cytokine in 
Experiment 2 (CK50 medium), whereas medium was 
supplemented with 20 ng/mL of each cytokine for Experiment 
3 (CK20 medium). Basal medium was used in control 
eBM-MSCs in the three experiments (control medium). 
One million eBM-MSCs at third passage from EQ01, EQ02 
and EQ03 were thawed at 37oC and seeded at 5,000 cells/cm2 in 
basal medium at 37oC and 5% CO2 until confluence reached 80 
to 90%, allowing readjustments of conditions prior to initiating 
the experiments. SF-, CK50-, CK20- or control-media were 
then added to the cells. Inflammatory exposure and their controls 
were carried out in triplicate for each animal in each experiment 
(SF, CK50, and CK20). Cells were cultured for 72 h in their 
corresponding media at 37oC and 5% CO2, after which eBM-MSCs 
were detached with 0.25% trypsin-EDTA (Sigma-Aldrich), 
washed three times with PBS (Gibco, USA) to completely 
remove inflammatory molecules, and then used for the different 
assays.
Proliferation assay
Cell proliferation after every inflammatory exposure and 
their controls was evaluated over seven days by MTT proliferation 
assay as previously described [28]. Viable cell numbers for the 
different samples were determined using a calibration curve 
consisting of nine triplicate points of increasing amounts of 
cells [28]. Basal medium was used as a blank. The cell doubling 
time for the control and inflammatory-stimulated eBM-MSCs 
from each experiment was calculated.
Tri-lineage differentiation assay
Control and inflammatory exposed cells were cultured in 
induction medium (differentiation) and basal medium (control) 
in triplicate according to each differentiation assay. For osteogenic 
differentiation, eBM-MSCs from each sample were seeded at 
20,000 cells/cm2 in 24-well plates. Osteogenic medium consisted 
of 10 nmol/L dexamethasone, 10 mmol/L -glycerophosphate 
and 100 mol/L ascorbate-2-phosphate (all from Sigma-Aldrich) 
supplemented basal medium. After 7 days, typical calcium 
deposit formation was assessed by Alizarin Red staining. To 
accomplish this, cells were fixed with 70% ethanol for 1 h at 
room temperature (RT), stained with 2% Alizarin Red stain (pH 
4.6) (Sigma-Aldrich) for 10 min (RT) and washed with PBS.
Equine BM-MSCs from each sample were seeded at 5,000 
cells/cm2 in 12-well plates for adipogenic differentiation. 
Adipogenic medium consisted of 1 mol/L dexamethasone, 500 
mol/L 3-isobutyl-1-methylxanthine, 200 mol/L indomethacin 
and 15% rabbit serum (all from Sigma-Aldrich) supplemented 
basal medium. After 15 days, typical fat droplets were evaluated 
by Oil Red O staining. Briefly, cells were fixed with 10% 
formalin (Sigma-Aldrich) for 15 min at RT, stained with 0.3% 
Oil Red O (Sigma-Aldrich) (dissolved in 60:40; isopropanol: 
distilled water) stain for 30 min at 37oC, then washed with 
distilled water. 
Chondrogenic differentiation was conducted in pellet culture. 
To accomplish this, approximately 300,000 eBM-MSCs from 
each sample were transferred to conic bottom 15 mL tubes, after 
which 400 L of chondrogenic differentiation medium were 
added and the samples were centrifuged at 300 × g for 5 min to 
pellet the cells. Chondrogenic medium consisted of 10% FBS, 
10 ng/mL TGF-3 (R&D Systems), ITS+ premix (Becton, 
Dickinson and Commpany), 40 g/mL proline, 50 g/mL 
ascorbate-2-phosphate, and 0.1 mol/L dexamethasone 
supplemented high glucose DMEM (all from Sigma-Aldrich). 
After 21 days, chondrogenic differentiation was evaluated by 
specific staining with Alcian blue staining. Pellets were fixed in 
10% formalin, embedded in paraffin and sectioned into 5 m 
sections. The sections were then hydrated with increasing 
gradients of alcohol, stained with Mayer’s haematoxylin and 
3% Alcian blue, rinsed with distilled water, dehydrated with 
decreasing amounts of alcohols and mounted.
Real time quantitative polymerase chain reaction (RT-qPCR)
Expression of genes coding for molecules related to proliferation 
(cyclooxygenase 1 [COX-1] COX-1, Cyclin D2) and apoptosis 
(BAX, BCL-2, BCL-XL, CASP-8, HSP-27, TNF-, IFN-) was 
assessed by RT-qPCR to investigate eBM-MSCs viability. A 
RNAspin Mini RNA Isolation Kit (GE Healthcare, UK) was 
used to isolate total mRNA from approximately 106 eBM-MSCs 
from each sample. Genomic DNA was removed using DNAse 
Turbo (Ambion, USA) and 1.5 g of mRNA from each sample 
were retrotranscripted to cDNA with a Superscript Reverse 
Transcriptase Kit (Life Technologies, USA). mRNA isolation 
and cDNA retrotranscription from osteogenic and adipogenic 
differentiation assays were performed using a Cells-to-cDNA II 
kit (Ambion). mRNA could not be isolated from differentiated 
CK20-eBM-MSCs or from cells undergoing chondrogenic 
differentiation because there was not enough sample to perform 
both staining and mRNA isolation. All processes were conducted 
according to manufacturer’s instructions.
A StepOne Real Time PCR System device (Applied Biosystems, 
USA) was used to perform and monitor RT-qPCR. All reactions 
were carried out in a total volume of 10 L with 2 L of cDNA 
as the template and Fast SYBR Green Master Mix (Applied 
Biosystems). Amplification and analysis were performed as 
previously described [27]. The expression levels of all genes in 
each sample were normalized by a normalization factor (NF), 
which was calculated as the geometric mean of the quantity of 
two housekeeping genes, GAPDH and B2M [15]. The Primer 
Express 2.0 software (Applied Biosystems) was used to design 
primers based on known equine sequences. Information about 
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Table 1. Primers used for gene expression by real time quantitative polymerase chain reaction (RT-qPCR). GenBank accession numbers 
of the sequences used for primers design. Primers (F: forward and R: reverse) and length of the amplicon in base pairs (bp)
Gene Accession number Primer sequence (5‘–3’) Amplicon size (bp)
Housekeeping
  GAPDH NM_001163856 F:GGCAAGTTCCATGGCACAGT 128
R:CACAACATATTCAGCACCAGCAT
  B2M NM_001082502.2 F: TCGTCCTGCTCGGGCTACT 102
R: ATTCTCTGCTGGGTGACGTGA
Characterization cell surface markers
  CD90 EU881920 F:TGCGAACTCCGCCTCTCT 93
R:GCTTATGCCCTCGCACTTG
  CD105 XM_001500078 F:GACGGAAAATGTGGTCAGTAATGA 100
R:GCGAGAGGCTCTCCGTGTT
  CD73 XM_001500115 F:GGGATTGTTGGATACACTTCAAAAG 90
R:GCTGCAACGCAGTGATTTCA
  CD44 NM_001085435 F: CCCACGGATCTGAAACAAGTG 95
R: TTCTGGAATTTGAGGTCTCCGTAT
  CD45 AY_114350 F:TGATTCCCAGAAATGACCATGTA 100
R:ACATTTTGGGCTTGTCCTGTAAC
  CD34 XM_001491596 F:CACTAAACCCTCTACATCATTTTCTCCTA 150
R:GGCAGATACCTTGAGTCAATTTCA
  MHC-I AB525081 F: CGTGAGCATCATTGTTGGC 92
R: TCCCTCTTTTTTCACCTGAGG
  MHC-II NM_001142816 F: AGCGGCGAGTTGAACCTACAGT 172
R: CGGATCAGACCTGTGGAGATGA
Proliferation related enzymes
  COX1 DQ246452 F: TCTATGCTACGCTCTGGCTACG 127
R: TTGATGGTCTCCCCGATGA
  Cyclin D2 XM_001494152 F: TCACGACTTCATCGAGCACATC 118
R: GGCGAACTTAAAGTCAGTGGCA
Molecules participating in apoptosis
  BAX XM_005596728.1 F: AGTGTCTCAAGCGCATCGG 104
R: CACTCGGAAAAAGACCTCGC
  BCL-2 Ryhner, 2008 F: GCCTATCTGGGCCACAAGT 200
R:TTTCCCTTTGGCAGTAAATAGC
  BCL-XL XM_001499714 F: GTCGGATCGCAACCTGGAT 100
R: GTTCCCGTAGAGTTCCACAAAGG
  CASP8 XM_001496753.2 F: CAATCCGATAGATGCACCAGG 101
R: AGGAGAATGCAGTCGTTGCC
  HSP-27 XM_001500212 F: GGCATTATGTAGAATCCATTGATCCT 78
R: CGGGCTGGTGATCTTCTT
Apoptosis-related proinflammatory cytokines
  TNF- EU438779 F: CATGTTGTAGCAAACCCCCAA 125
R: TACAGCCCATCCAATGGTACC
  IFN- EU000433 F: AACCTAAAGGAATATTTTAACGCAAGT 101
R: TTTTTGTCACTATCCTCTTTCCAGTT
Osteogenic markers
  ALP XM_001504312 F: GATGGCCTGAACCTCATCGA 92
R: AGTTCGGTCCGGTTCCAGAT
  RUNX2 XM_001502519.3 F: CTCCAACCCACGAATGCACTA 80
R: CGGACATACCGAGGGACATG
Adipogenic markers
  LPL XM_001489577 F:TGTATGAGAGTTGGGTGCCAAA 70
R:GCCAGTCCACCACAATGACAT
  PPAR XM_001492411 F:TGCAAGGGTTTCTTCCGGA 104
R:GCAAGGCATTTCTGAAACCG
Genes were grouped in agreement with the functions and implications of encoded molecules as follows to facilitate the posterior analysis: housekeeping, 
cell surface markers, proliferation related enzymes, molecules participating in apoptosis, apoptosis-related proinflammatory cytokines, osteogenic markers 
and adipogenic markers.
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Fig. 1. Proliferation related enzymes of control and inflammatory- exposed eBM-MSCs from Experiment 1 (A), 2 (B) and 3 (C) over 7 days.
eBM-MSC proliferation potential was unaltered after SF exposure; however, this property was diminished after culturing cells with both
CK20 and CK50 media. Proliferation was evaluated by MTT assay. The means ± SEM (n = 3) of the cell count are shown for each 
experiment at each time-point in both linear graphs (*p ＜ 0.05) and a data table.
primers is shown in Table 1. 
Statistical analysis
Data obtained in this study were subjected to statistical 
analysis using SPSS 15.0 (SPSS, USA). Proliferation data are 
presented as the means (n = 3) ± SEM cell count of stimulated and 
unstimulated eBM-MSCs at each time point (7 days) for each 
experiment. Differences in mean cell numbers between 
stimulated and unstimulated eBM-MSCs from each day were 
analyzed by paired Student’s t tests separately for each experiment. 
RT-qPCR data are reported as the means (n = 3) ± SEM fold 
increase or decrease of stimulated eBM-MSCs gene expression 
over unstimulated control eBM-MSC. Differences between 
eBM-MSCs from every inflammatory condition (SF, CK50 and 
CK20) and their controls were analyzed by paired Student’s 
t-tests. The significance level was set at p ＜ 0.05 for all analyses.
Results
Isolation and characterization of eBM-MSCS
Cells obtained from EQ01, EQ02 and EQ03 BM aspirates 
showed plastic-adherent fibroblast-like morphology and were 
positive for the surface markers CD90, CD105, CD44 and 
MHC-I and negative for MHC-II by flow cytometry. All samples 
expressed transcripts for CD105, CD90, CD73, CD44 and 
MHC-I, but not for CD34 and CD45, and low levels for MHC-II 
by RT-qPCR. The ability of tri-lineage was confirmed in all 
cases (data not shown).
Inflammatory synovial fluid harvesting 
The average total protein measurement in the harvested 
synovial fluid was 2.25 g/dL. The SAA concentration was 
0.585 × 10−3 g/dL and the Hp concentration was 0.023 g/dL. 
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Fig. 3. eBM-MSCs expression of certain genes encoding apoptosis-related molecules can be affected by proinflammatory cytokines.
Gene expression of each gene in every experiment is represented as the mean ± SEM (n = 3) fold increase or decrease compared to
the corresponding control from each experiment. (A) Expression of genes encoding molecules directly participating in the apoptosis 
mechanisms BAX, BCL-2, BCL-XL, CASP8, and HSP27. (B) Expression of genes encoding proinflammatory cytokines related to 
apoptosis TNF- and IFN-. NE, no expression. *p ＜ 0.05 and **p ＜ 0.01.
Table 2. Cell doubling time (DT) for control and inflammatory- 
stimulated eBM-MSCs
DT mean ± SEM
(d)
Control
Inflammatory 
stimulation
Experiment 1
 (SF)
2.434 ± 0.197 2.507 ± 0.219
Experiment 2 
(CK50)
1.857 ± 0.160 9.001 ± 2.51
EXperiment 3 
(CK20)
2.676 ± 0.195 10.729 ± 1.923
Results are shown as the mean ± SEM (n=3) of DT for control and 
inflammatory exposed eBM-MSCs from Experiment 1 (SF), 2 (CK50) and 3 
(CK20). Cell doubling time was calculated according to the formula: CD 
= ln [(Nf/Ni)/ln2] and DT = CT/CD, where DT, cell doubling time; Nf, 
final number of cells; Ni, initial number of cells; CD, cell doubling 
number.
Fig. 2. eBM-MSCs expression of proliferation related enzymes is
influenced by inflammatory stimulation. Gene expression of 
COX-1 and CyclinD2 in inflammatory exposed eBM-MSCs is 
expressed as the mean ± SEM (n = 3) fold increase or decrease
compared to the corresponding control from each experiment 
(*p ＜ 0.05). 
These data confirmed the inflammatory status of the synovial 
fluid, and when combined with the cytological examination 
discarded a septic origin of the joint inflammation. 
Effects of inflammatory environment on eBM-MSCs 
proliferation
For the MTT assay, the total number of viable cells from 
every sample was determined by extrapolation from the 
calibration curve: y = 9 × 10−6 x + 0.0805, r2 = 0,939, where y 
represents the optical density of the well and x represents the 
amount of cells. Synovial fluid-exposed eBM-MSCs grew in a 
similar manner to control cells (panel A in Fig. 1). In both CK50 
and CK20 experiments, the number of CK-stimulated cells 
decreased until the fourth day, then increased slightly until the 
sixth day, but still remained below the initial level (panels B and 
C in Fig. 1). Significant differences (p ＜ 0.05) in the number of 
cells were observed between control and CK-exposed cells in 
all days under both CK20 and CK50 conditions. As shown in 
Table 2, the cell doubling times were also similar between 
control and SF stimulated eBM-MSCs, but increased greatly in 
both CK50 and CK20-stimulated eBM-MSCs. The 
proliferation related genes COX-1 and Cyclin D2 were 
significantly downregulated under the CK50 and CK20 
conditions (p ＜ 0.05), and their expression remained similar in 
the SF experiment (Fig. 2). 
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Fig. 4. Staining for osteogenic, adipogenic and chondrogenic 
differentiation of control and inflammatory-stimulated 
eBM-MSCs from three experiments. (A) Alizarin red staining of 
eBM-MSCs cultured for 7 days in osteogenic differentiation 
medium from control and Experiment 1–3. (B) Oil red O staining 
of eBM-MSCs cultured for 15 days in adipogenic differentiation 
medium from control and Experiment 1–3. (C) Haematoxylin 
and Alcian blue staining of pellets cultured for 21 days in 
chondrogenic medium from control and Experiment 1–3. Scale 
bars = 500 m (A and B), 2 m (C). 10× (A), 4× (B), 20×(C).
Effect of inflammatory environment on apoptosis gene 
expression of eBM-MSCs
Apoptosis-related gene expression was studied in CK50 
and CK20 exposed eBM-MSCs. BAX was significantly 
downregulated under both CK50 (p ＜ 0.01) and CK20 (p ＜ 
0.05) conditions, while BCL-2 was only significantly 
downregulated under CK20 conditions. CASP8 showed a trend 
to increase its expression under both CK conditions. The 
anti-apoptotic factor heat shock protein 27 (HSP27) was 
significantly downregulated under CK50 conditions (panel A in 
Fig. 3). TNF- expression was downregulated and no-expression 
was found for IFN- under SF conditions, whereas significant 
upregulation of TNF- (p ＜ 0.05) and IFN- (p ＜ 0.05) was 
observed in CK50 and CK20, respectively (panel B in Fig. 3). 
Effect of inflammatory environment on eBM-MSCs 
differentiation potential
Osteogenic, adipogenic and chondrogenic differentiation 
were achieved in control (unstimulated) cells from the three 
experiments. Spontaneous differentiation was not observed in 
any of the non-differentiated controls.
Osteogenic differentiation was confirmed in SF-exposed 
eBM-MSCs by positive staining of the calcium deposits with 
Alizarin red. CK-stimulated eBM-MSCs showed irregular 
morphology, but did not form a calcium-rich matrix (panel A in 
Fig. 4). Alkaline phosphatase (ALP) and Runt-related transcription 
factor 2 (RUNX2) gene expression was not significantly 
modified by SF conditions, but the expression of both genes in 
SF-exposed eBM-MSCs was slightly higher than in the 
differentiated control (panel A in Fig. 5). Expression of ALP and 
RUNX2 was downregulated in CK50-exposed eBM-MSCs 
compared to the differentiated control; however, this 
downregulation was only significant for RUNX2 (p ＜ 0.05) 
(panel B in Fig. 5). ALP increased by 18.93-fold in 
SF-differentiated cells relative to the control, but only by 
2.49 in CK50-differentiated cells. RUNX2 expression in 
SF-differentiated cells increased by 4.48-fold, whereas a 
3.85-fold decrease was observed in CK50-differentiated cells 
(panels A and B in Fig. 5).
Oil red O staining revealed lipid droplets in SF-exposed 
eBM-MSCs undergoing adipogenic induction. Both CK50 and 
CK20-stimulated cells did not display an adipogenic phenotype 
(panel B in Fig. 4). Peroxisome proliferator-activated receptor 
 (PPAR) and lipoprotein lipase (LPL) mRNA levels were not 
significantly modified by SF exposure (panel C in Fig. 5). LPL 
and PPAR in CK50- and SF-differentiated cells showed similar 
increases relative to non-differentiated control cells, but both 
genes were significantly downregulated in CK50-exposed cells 
(p ＜0.05) compared to unstimulated differentiated cells (panel 
D in Fig. 5).
Synovial fluid-exposed cells maintained their chondrogenic 
differentiation potential, as indicated by the positive blue 
staining of the extracellular matrix upon Alcian blue staining. 
However, neither CK50 nor CK20-exposed eBM-MSCs 
differentiated into the chondrogenic lineage, and they formed 
irregular discoid pellets instead of the typical spherical shape 
(panel C in Fig. 4).
Discussion
Both APPs analyzed in the inflammatory synovial fluid were 
above the reference ranges [1,14], which is in agreement with 
the expected changes for these proteins [14]. The inflammatory 
environment provided by cytokine priming resulted in a 
remarkable viability impairment of eBM-MSCs, whereas SF 
conditions did not alter their regular growth. The significant 
down-regulation of COX1 and CyclinD2, enzymes involved in 
the regulation of the cell cycle and cell proliferation [33,36], in 
both CK experiments might be related to the failed proliferation 
of eBM-MSCs [33,36]. Thus, treatment with both cytokine 
concentrations appeared to be cytotoxic. To elucidate this 
phenomenon under CK conditions, the expression of several 
genes involved in the apoptosis process was investigated. 
BCL2-Associated X Protein (BAX) is a proapoptotic gene and 
BCL-2 is an antiapoptotic gene, both of which are involved in 
the apoptosis mitochondrial pathway [13]. While BAX was 
downregulated under both CK conditions, BCL-2 expression 
showed contrasting results between CK50 and CK20 experiments, 
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Fig. 5. Effect of inflammatory conditions on gene expression of differentiation markers. Influence of the three inflammatory conditions 
tested on eBM-MSC expression of genes encoding osteogenesis (ALP and RUNX2) and adipogenesis (LPL and PPAR) markers. The 
results are expressed as the mean ± SEM (n = 3) fold increase or decrease of differentiated control cells (CTRL.DIF), non-differentiated
SF or CK50 exposed eBM-MSCs (SF.NON-DIF and CK50.NON-DIF) and differentiated SF or CK50 exposed eBM-MSCs (SF.DIF and 
CK50.DIF) over control unstimulated and non-differentiated cells (CTRL.NON-DIF). The white bar in all graphs (1 ± 0) represents the 
CTRL.NON-DIF fold change over itself relative to the fold increase or decrease under other conditions. (A and B) Gene expression of 
osteogenesis markers in cells from Experiment 1 (A) and Experiment 2 (B). (C and D) Gene expression of adipogenesis markers in cells
from Experiment 1(C) and Experiment 2 (D). 
which suggest that the apoptosis mitochondrial pathway might 
not be involved. However, the apoptosis death receptor 
pathway might be involved since CASP8 showed a trend to 
upregulation [13]. In addition, the downregulation of HSP27, 
which protects against injury-related MSC apoptosis [34], 
might be associated with failed cell development and cell 
differentiation [34]. TNF- and IFN- have a synergic effect in 
the induction of apoptosis by the death receptor signaling 
pathway in MSCs [20]. Additionally, TNF- converts the 
signaling of the non-apoptotic receptor Fas, which is activated 
by IFN-, into a CASP8 proapoptotic cascade in MSCs [20,38]. 
Based on these findings, the apoptotic process might be 
involved in the low viability and plasticity of CK-exposed 
eBM-MSCs. 
Reduction of the tri-lineage differentiation ability of MSCs 
by proinflammatory cytokines has been described in other 
species. T-cells mediated secretion of TNF- and IFN- 
synergistically hamper osteogenesis, chondrogenesis [6,9,23] 
and adipogenesis [17]. TNF- or IL-1 exposure significantly 
reduces the gene expression of osteogenic, adipogenic and 
chondrogenic markers in murine MSCs [17]. In humans and 
rats, these cytokines inhibit the expression of the osteoblast 
differentiation transcription factor, RUNX2 [7,9]. Moreover, 
TNF- plays a dual role in osteogenesis. On the one hand, it 
inhibits the osteoblast differentiation transcription factor 
RUNX2 [9]. On the other hand, TNF- can enhance the MSC 
osteogenic differentiation in a dose-dependent manner, although 
this effect is avoided in the presence of anti-inflammatory 
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agents, such as dexamethasone, which is added to the 
osteogenic-induction media [22]. It has been proposed that the 
inhibition of osteoblast differentiation by TNF- occurs 
through the p55 TNF receptor [10]. High secretion of IFN- by 
immune cells has also been shown to prevent osteogenesis in 
MSCs in allogeneic implants in mice by dramatically reducing 
the expression of ALP and RUNX2 [6]. Our results agreed with 
those of previous reports in others species since the transcript 
levels of ALP and RUNX2 detected were lower in the presence 
of TNF- and IFN-. Adipogenesis could also be impaired by 
inflammatory conditions because high levels of proinflammatory 
cytokines, such as TNF-, lead to a reduction in PPAR 
expression by MSCs [4]. In agreement, PPAR gene expression 
was down-regulated under our CK conditions, resulting in a 
commitment of adipogenic differentiation. TNF- and IFN- 
have also been described as inhibitors of chondrogenesis and 
collagen formation in rat and mouse MSCs [17,24]. 
Chondrogenesis has been shown to be hindered through the 
inhibition of the chondrogenic factor Sox9 caused by these 
cytokines [23]. According to these reports, our CK conditions 
also led to a lack of chondrogenic potential in eBM-MSCs. The 
effects of proinflammatory cytokines on MSC differentiation 
could vary between species and, to our knowledge, this is the 
first time that this effect has been studied on equine MSCs. 
Overall, our results support the findings reported for other species 
[7,17] demonstrating the inhibitory effect of proinflammatory 
cytokines on the tri-lineage differentiation of eBM-MSCs. 
The natural joint environment could be favorable for 
chondrogenic differentiation [12,25]. However, when 
proinflammatory cytokines are present in high amounts, synovial 
fluid turns into an inflammatory environment, preventing 
chondrogenesis [19]. Depending on the level of proinflammatory 
cytokines, inflammatory synovial fluid could be more or less 
harmful for chondrogenesis and cartilage matrix formation (i.e., 
rheumatoid arthritis vs. OA) [16]. Under our experimental 
conditions, tri-lineage differentiation was achieved by 
SF-exposed eBM-MSCs, suggesting that a moderate 
inflammatory status of the synovial fluid did not have a significant 
effect on eBM-MSCs differentiation ability.
The present research provides novel results about eBM-MSCs 
in inflammatory environments that can contribute to their 
intra-articular use for therapeutic applications. In summary, an 
inflammatory synovial environment is satisfactorily tolerated 
by eBM-MSCs, which maintained their proliferation and 
differentiation abilities, encouraging the use of cell therapy for 
joint pathologies. In contrast, cytokine priming tested in this 
study negatively affected the eBM-MSCs proliferation and 
differentiation abilities, and appeared to induce apoptosis, 
possibly compromising their in vivo efficacy and their 
therapeutic potential. 
Acknowledgments
This study was supported by the Ministry of Economy and 
Competitiveness, Spain (AGL2011-28609) and by the 
Government of  Aragón (Research Group LAGENBIO). Laura 
Barrachina is funded by a doctoral grant from the Government 
of  Aragón. Ana Rosa Remacha is funded by a doctoral grant 
(EPIF) from the University of Zaragoza. We thank the horse 
owners for allowing their animals to be part of this study and the 
Veterinary Hospital of the University of Zaragoza for facilitating 
access to equine patients and allowing the use of its installations 
for collecting samples. We also acknowledge the Department of 
Biochemistry and Molecular and Cellular Biology of the 
University of Zaragoza for the help with analyses of acute phase 
proteins in the synovial fluid.
Conflict of Interest
The authors declare no conflict of interest.
References
1. Basile RC, Ferraz GC, Carvalho MP, Albernaz RM, Araújo 
RA, Fagliari JJ, Queiroz-Neto A. Physiological concentrations 
of acute-phase proteins and immunoglobulins in equine 
synovial fluid. J Equine Vet Sci 2013, 33, 201-204.
2. Casella S, Fazio F, Giannetto C, Giudice E, Piccione G. 
Influence of transportation on serum concentrations of acute 
phase proteins in horse. Res Vet Sci 2012, 93, 914-917.
3. Cellular, Tissue, and Gene Therapies Advisory Committee. 
Cellular products for joint surface repair. Briefing document 
of the 38th Meeting of Cellular, Tissue, and Gene Therapies 
Advisory Committee. 3-4 March 2005, Silver Spring, USA.
4. Cortez M, Carmo LS, Rogero MM, Borelli P, Fock RA. A 
high-fat diet increases IL-1, IL-6, and TNF- production by 
increasing NF-B and attenuating PPAR- expression in 
bone marrow mesenchymal stem cells. Inflammation 2013, 
36, 379-386.
5. Cuerquis J, Romieu-Mourez R, François M, Routy JP, 
Young YK, Zhao J, Eliopoulos N. Human mesenchymal 
stromal cells transiently increase cytokine production by 
activated T cells before suppressing T-cell proliferation: effect 
of interferon- and tumor necrosis factor- stimulation. 
Cytotherapy 2014, 16, 191-202.
6. Dighe AS, Yang S, Madhu V, Balian G, Cui Q. Interferon 
gamma and T cells inhibit osteogenesis induced by allogeneic 
mesenchymal stromal cells. J Orthop Res 2013, 31, 227-234.
7. Ding J, Ghali O, Lencel P, Broux O, Chauveau C, Devedjian 
JC, Hardouin P, Magne D. TNF- and IL-1 inhibit RUNX2 
and collagen expression but increase alkaline phosphatase 
activity and mineralization in human mesenchymal stem 
cells. Life Sci 2009, 84, 499-504.
8. Ferris DJ, Frisbie DD, Kisiday JD, McIlwraith CW, Hague 
BA, Major MD, Schneider RK, Zubrod CJ, Kawcak CE, 
Goodrich LR. Clinical outcome after intra-articular 
48    Laura Barrachina et al.
Journal of Veterinary Science
administration of bone marrow derived mesenchymal stem 
cells in 33 horses with stifle injury. Vet Surg 2014, 43, 
255-265.
9. Gilbert L, He X, Farmer P, Rubin J, Drissi H, van Wijnen AJ, 
Lian JB, Stein GS, Nanes MS. Expression of the osteoblast 
differentiation factor RUNX2 (Cbfa1/AML3/Pebp2A) is 
inhibited by tumor necrosis factor-. J Biol Chem 2002, 277, 
2695-2701.
10. Gilbert LC, Rubin J, Nanes MS. The p55 TNF receptor 
mediates TNF inhibition of osteoblast differentiation 
independently of apoptosis. Am J Physiol Endocrinol Metab 
2005, 288, E1011-1018.
11. Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis 
in the horse - a review. Vet J 2006, 171, 51-69.
12. Hegewald AA, Ringe J, Bartel J, Krüger I, Notter M, 
Barnewitz D, Kaps C, Sittinger M. Hyaluronic acid and 
autologous synovial fluid induce chondrogenic differentiation 
of equine mesenchymal stem cells: a preliminary study. 
Tissue Cell 2004, 36, 431-438.
13. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell 
death. N Engl J Med 2009, 361, 1570-1583.
14. Jacobsen S, Thomsen MH, Nanni S. Concentrations of 
serum amyloid A in serum and synovial fluid from healthy 
horses and horses with joint disease. Am J Vet Res 2006, 67, 
1738-1742.
15. Kolm G, Klein D, Knapp E, Watanabe K, Walter I. 
Lactoferrin expression in the horse endometrium: relevance 
in persisting mating-induced endometritis. Vet Immunol 
Immunopathol 2006, 114, 159-167.
16. Krüger JP, Endres M, Neumann K, Stuhlmüller B, 
Morawietz L, Häupl T, Kaps C. Chondrogenic differentiation 
of human subchondral progenitor cells is affected by 
synovial fluid from donors with osteoarthritis or rheumatoid 
arthritis. J Orthop Surg Res 2012, 7, 10.
17. Lacey DC, Simmons PJ, Graves SE, Hamilton JA. 
Proinflammatory cytokines inhibit osteogenic differentiation 
from stem cells: implications for bone repair during 
inflammation. Osteoarthritis Cartilage 2009, 17, 735-742.
18. Leijs MJC, van Buul GM, Lubberts E, Bos PK, Verhaar JAN, 
Hoogduijn MJ, van Osch GJVM. Effect of arthritic synovial 
fluids on the expression of immunomodulatory factors by 
mesenchymal stem cells: an explorative in vitro study. Front 
Immunol 2012, 3, 231.
19. Liu X, Xu Y, Chen S, Tan Z, Xiong K, Li Y, Ye Y, Luo ZP, He 
F, Gong Y. Rescue of proinflammatory cytokine-inhibited 
chondrogenesis by the antiarthritic effect of melatonin in 
synovium mesenchymal stem cells via suppression of 
reactive oxygen species and matrix metalloproteinases. Free 
Radic Biol Med 2014, 68, 234-246.
20. Liu Y, Wang L, Kikuiri T, Akiyama K, Chen C, Xu X, Yang 
R, Chen W, Wang S, Shi S. Mesenchymal stem cell-based 
tissue regeneration is governed by recipient T lymphocytes 
via IFN- and TNF-. Nat Med 2011, 17, 1594-1601.
21. Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y. Immunobiology 
of mesenchymal stem cells. Cell Death Differ 2014, 21, 
216-225.
22. Mountziaris PM, Tzouanas SN, Mikos AG. Dose effect of 
tumor necrosis factor- on in vitro osteogenic differentiation 
of mesenchymal stem cells on biodegradable polymeric 
microfiber scaffolds. Biomaterials 2010, 31, 1666-1675.
23. Murakami S, Lefebvre V, de Crombrugghe B. Potent inhibition 
of the master chondrogenic factor Sox9 gene by interleukin-1 
and tumor necrosis factor-. J Biol Chem 2000, 275, 3687- 
3692.
24. Nanes MS, McKoy WM, Marx SJ. Inhibitory effects of 
tumor necrosis factor- and interferon- on deoxyribonucleic 
acid and collagen synthesis by rat osteosarcoma cells (ROS 
17/2.8). Endocrinology 1989, 124, 339-345.
25. Ogueta S, Muñoz J, Obregon E, Delgado-Baeza E, García- 
Ruiz JP. Prolactin is a component of the human synovial 
liquid and modulates the growth and chondrogenic 
differentiation of bone marrow-derived mesenchymal stem 
cells. Mol Cell Endocrinol 2002, 190, 51-63.
26. Paterson YZ, Rash N, Garvican ER, Paillot R, Guest DJ. 
Equine mesenchymal stromal cells and embryo-derived 
stem cells are immune privileged in vitro. Stem Cell Res 
Ther 2014, 5, 90.
27. Ranera B, Lyahyai J, Romero A, Vázquez FJ, Remacha AR, 
Bernal ML, Zaragoza P, Rodellar C, Martín-Burriel I. 
Immunophenotype and gene expression profiles of cell 
surface markers of mesenchymal stem cells derived from 
equine bone marrow and adipose tissue. Vet Immunol 
Immunopathol 2011, 144, 147-154.
28. Ranera B, Ordovás L, Lyahyai J, Bernal ML, Fernandes F, 
Remacha AR, Romero A, Vázquez FJ, Osta R, Cons C, 
Varona L, Zaragoza P, Martín-Burriel I, Rodellar C. 
Comparative study of equine bone marrow and adipose 
tissue-derived mesenchymal stromal cells. Equine Vet J 
2012, 44, 33-42.
29. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, 
Zhao RC, Shi Y. Mesenchymal stem cell-mediated 
immunosuppression occurs via concerted action of 
chemokines and nitric oxide. Cell Stem Cell 2008, 2, 
141-150.
30. Ren G, Zhao X, Zhang L, Zhang J, L’Huillier A, Ling W, 
Roberts AI, Le AD, Shi S, Shao C, Shi Y. Inflammatory 
cytokine-induced intercellular adhesion molecule-1 and 
vascular cell adhesion molecule-1 in mesenchymal stem 
cells are critical for immunosuppression. J Immunol 2010, 
184, 2321-2328.
31. Roberts S, Genever P, McCaskie A, De Bari C. Prospects of 
stem cell therapy in osteoarthritis. Regen Med 2011, 6, 
351-366.
32. Schlueter AE, Orth MW. Equine osteoarthritis: a brief 
review of the disease and its causes. Equine Comp Exerc 
Physiol 2004, 1, 221-231.
33. Shahdadfar A, Frønsdal K, Haug T, Reinholt FP, 
Brinchmann JE. In vitro expansion of human mesenchymal 
stem cells: choice of serum is a determinant of cell proliferation, 
differentiation, gene expression, and transcriptome stability. 
Stem Cells 2005, 23, 1357-1366.
34. Son TW, Yun SP, Yong MS, Seo BN, Ryu JM, Youn HY, Oh 
YM, Han HJ. Netrin-1 protects hypoxia-induced mitochondrial 
apoptosis through HSP27 expression via DCC- and integrin 
64-dependent Akt, GSK-3, and HSF-1 in mesenchymal 
stem cells. Cell Death Dis 2013, 4, e563.
35. van Buul GM, Villafuertes E, Bos PK, Waarsing JH, Kops N, 
Narcisi R, Weinans H, Verhaar JAN, Bernsen MR, van Osch 
Effect of inflammation on properties of equine mesenchymal stem cells    49
www.vetsci.org
GJVM. Mesenchymal stem cells secrete factors that inhibit 
inflammatory processes in short-term osteoarthritic synovium 
and cartilage explant culture. Osteoarthritis Cartilage 2012, 
20, 1186-1196.
36. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. 
Annu Rev Pharmacol Toxicol 1998, 38, 97-120.
37. Vézina Audette R, Lavoie-Lamoureux A, Lavoie JP, Laverty 
S. Inflammatory stimuli differentially modulate the 
transcription of paracrine signaling molecules of equine 
bone marrow multipotent mesenchymal stromal cells. 
Osteoarthritis Cartilage 2013, 21, 1116-1124.
38. Wang L, Zhao Y, Liu Y, Akiyama K, Chen C, Qu C, Jin Y, Shi 
S. IFN- and TNF- synergistically induce mesenchymal 
stem cell impairment and tumorigenesis via NFB signaling. 
Stem Cells 2013, 31, 1383-1395.
39. Zimmermann JA, McDevitt TC. Pre-conditioning 
mesenchymal stromal cell spheroids for immunomodulatory 
paracrine factor secretion. Cytotherapy 2014, 16, 331-345. 
